Clinical DataBudoprutug has already demonstrated strong proof-of-concept data in primary membranous nephropathy (pMN), an indication with blockbuster potential on its own.
Financial StabilityThe company ended with significant cash reserves, sufficient to fund operations through 2027, providing financial stability.
Product DevelopmentThe potential of the company’s CD19 antibody, budoprutug, being developed across a range of autoimmune indications supports an Outperform rating.